379 related articles for article (PubMed ID: 16098861)
1. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening.
Huang T; Owolabi T; Summers AM; Meier C; Wyatt PR
Am J Obstet Gynecol; 2005 Aug; 193(2):395-403. PubMed ID: 16098861
[TBL] [Abstract][Full Text] [Related]
2. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
3. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
4. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
Benn PA; Ying J; Beazoglou T; Egan JF
Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol.
Hogge WA; Fraer L; Melegari T
Am J Obstet Gynecol; 2001 Aug; 185(2):289-93. PubMed ID: 11518881
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum screening for birth defects: results of a Connecticut regional program.
Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
[TBL] [Abstract][Full Text] [Related]
7. [Maternal serum screening for Down syndrome and neural tube defects].
van Rijn M; Christiaens GC; van der Schouw YT; Hagenaars AM; de Pater JM; Visser GH
Ned Tijdschr Geneeskd; 1998 Feb; 142(8):409-15. PubMed ID: 9562776
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum screening for neural tube defects and fetal chromosome abnormalities.
Rose NC; Mennuti MT
West J Med; 1993 Sep; 159(3):312-7. PubMed ID: 7694429
[TBL] [Abstract][Full Text] [Related]
9. Maternal serum screening and trisomy 16 confined to the placenta.
Groli C; Cerri V; Tarantini M; Bellotti D; Jacobello C; Gianello R; Zanini R; Lancetti S; Zaglio S
Prenat Diagn; 1996 Aug; 16(8):685-9. PubMed ID: 8878276
[TBL] [Abstract][Full Text] [Related]
10. Maternal serum screening of Palestinian women in the West Bank.
Husseini A; Akkawi M
East Mediterr Health J; 2005 Jul; 11(4):824-7. PubMed ID: 16700399
[TBL] [Abstract][Full Text] [Related]
11. Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz syndrome (SLOS).
Craig WY; Haddow JE; Palomaki GE; Roberson M
Prenat Diagn; 2007 May; 27(5):409-14. PubMed ID: 17286308
[TBL] [Abstract][Full Text] [Related]
12. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
[TBL] [Abstract][Full Text] [Related]
13. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.
Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987
[TBL] [Abstract][Full Text] [Related]
14. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.
Saller DN; Canick JA; Blitzer MG; Palomaki GE; Schwartz S; Blakemore KJ; Haddow JE
Prenat Diagn; 1999 Sep; 19(9):813-6. PubMed ID: 10521837
[TBL] [Abstract][Full Text] [Related]
15. Sequential pathways of testing after first-trimester screening for trisomy 21.
Platt LD; Greene N; Johnson A; Zachary J; Thom E; Krantz D; Simpson JL; Silver RK; Snijders RJ; Goetzl L; Pergament E; Filkins K; Mahoney MJ; Hogge WA; Wilson RD; Mohide P; Hershey D; MacGregor S; Bahado-Singh R; Jackson LG; Wapner R;
Obstet Gynecol; 2004 Oct; 104(4):661-6. PubMed ID: 15458882
[TBL] [Abstract][Full Text] [Related]
16. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies.
Bahado-Singh RO; Oz U; Shahabi S; Mahoney MJ; Baumgarten A; Cole LA
Am J Obstet Gynecol; 2000 Nov; 183(5):1114-8. PubMed ID: 11084551
[TBL] [Abstract][Full Text] [Related]
17. [Prenatal serum screening of aneuploidy and of neural tube defects in the second trimester of pregnancy among the population of Luxembourg. Evaluation of risk by the triple test (AFP+THCG+UE3)].
Thix J
Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(1):25-9. PubMed ID: 9303823
[TBL] [Abstract][Full Text] [Related]
18. Second trimester prenatal screening for Down syndrome: the associations between the levels of serum markers in successive pregnancies.
Huang T; Boucher K; Summers AM
Prenat Diagn; 2007 Dec; 27(12):1138-42. PubMed ID: 17960787
[TBL] [Abstract][Full Text] [Related]
19. First trimester predictors of adverse pregnancy outcomes.
Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
[TBL] [Abstract][Full Text] [Related]
20. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
Christiaens GC; Hagenaars AM; Akkerman C; De France HF
Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
